Listeria-Based Vaccine against Cutaneous Leishmaniasis
- Detailed Technology Description
- This vaccine is based on Listeria monocytogenes that has been engineered as follows: deletion of two Listeria genes involved in growth and cell-to-cell spread; and insertion of the sandfly salivary protein gene LJM11.
- Others
-
None
- *Abstract
-
This vaccine is based on Listeria monocytogenes that has been engineered as follows:
- Deletion of two Listeria genes involved in growth and cell-to-cell spread; and
- Insertion of the sandfly salivary protein gene LJM11
Leishmaniasis, a disease transmitted by sandflies infected with leishmania, is listed under the Center for Disease Control’s Neglected Tropical Disease, defined as “a group of parasitic and bacterial diseases that cause substantial illness for more than one billion people globally”. Second only to malaria in terms of prevalence, Leishmaniasis is endemic in 88 countries.
Cutaneous Leishmaniasis is one form of the disease and is characterized by skin ulcers, severe scarring and social stigmatization. 1-1.5 million new cases of the cutaneous form occur globally each year.
Potential Commercial Application:
- Vaccine for cutaneous Leishmaniasis
- *Licensing
- Phillip Owh, Senior Technology Commercialization and Liaison Officerpo62@cornell.edu607-254-4508
- Country/Region
- USA
For more information, please click Here
